Neurodiagnostics Market.

...

Geographically segmentation:

100 million people in North America and Europe are suffering from brain or nervous system disorders (Alzheimer, schizophrenia, Parkinson’s disease, sleep disorders). Bothe regions account for the largest share of the market.

Then we have few in Asia pacific and rest of the world.

Likewise, according to the National Institute of Mental health in the U.S. about 1 in 4 adults suffer from brain disorders every year; with almost 6% of the population suffer from serious disabilities.

Over 2 billion people worldwide currently suffer from a brain and nervous system illnesses and the global annual economic burden of brain-related illnesses has reached over $3 trillion. Brain-related illnesses include: addiction, Alzheimer’s disease, anxiety, ALS, attention disorders, autism, depression, epilepsy, hearing loss, Huntington’s disease, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson’s disease, post traumatic stress, retinal disorders, schizophrenia, stroke, traumatic brain injury and more.

Industry revenue, and growth:

In 2013, the 800 companies involved in the global neurotech industry generated $160 billion in revenue with 4% growth. The revenue for the three sectors in the industry breaks out as follows: neuropharmaceuticals had revenues of $134.5 billion and 2% growth.

neurodevices had revenues of $10.1 billion and 7% growth.

Neurodiagnostics generated revenues of $16.1 billion and 2% annual growth (NeuroInsights).

In 2013, global venture capital investment in neurotech companies (including drugs, devices, software and diagnostics) was up 12% to $1.44 billion, while overall life science investing was down 1% to $6.6 billion. In 2013, the total number of neurotech venture capital deals was down slightly to 152 deals, while over 200 different investor groups participated in these financings. Since 2000, private venture capital funds have invested over $19 billion in promising neurotech companies.

Neuroscience has increased from around $2.5 billion to $5.4 billion annually, accounting for approximately a sixth of the NIH budget.

Contributing to the global basic neuroscience funding ecosystem are the European Union, United Kingdom, Canada, China, Japan and several other countries that collectively invest an estimated $2 billion a year. In addition, billionaire philanthropists and their foundations like Paul Allen, Howard Hughes Medical Institute, Eli Broad, the Stanley family and Patrick and Lore McGovern, have in invested several billion dollars over the past decade in supporting innovative brain research.

Importantly, on the translational research front, the pharmaceutical industry invests a massive amount each year on neuroscience drug development, an estimated $25 billion, while medtech and diagnostics companies are investing an estimated $1 billion in trials for new neurodevices and diagnostics for brain and nervous system illnesses.

While the annual investment in neurotech for uses beyond medicine remains modest, on the order of a few hundreds of millions of dollars, this doesn’t mean that these applications won’t have a broad impact. Today the use of neurotech as applied to education, entertainment, wellness and information technology is small, but each of these has the potential to impact many of our lives in important ways.